The hypothetical question that must appear, is obviously, if the CellSearchTM System and other immunoaffinity - positive selection/enrichment based systems will evolve further into a system that is more capable to detect specific cancer entities by utilizing another selection of antigens present on cancer derived CTCs, for example Glypican-3, ASGPR1 and HepPar1 as for liver cancer derived CTCs 88-90. Here, ASGR1 is linked to cancer.